Charlene Mantia

11PUBLICATIONS
72CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 27, 2026
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial.

Matthew D Galsky, Charlene Mantia, Michaela Bowden

|Jan 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.

Hollis Viray, Charlene M Mantia, Opeyemi A Jegede

|Jan 26, 2026
ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer.

Ilana B Epstein, Adetolani Odogiyon, Stephanie Berg

|Jan 12, 2026
Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2.

Emre Yekedüz, Weiwei Bian, Stephanie E Siegmund

|Aug 12, 2025
Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer.

Jude Owiredu, Betul Ersoy-Fazlioglu, Larysa Poluben

|Jul 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.

Charlene M Mantia, Opeyemi A Jegede, David F McDermott

Pageof 2

Frequent Collaborators

4 joint publications

Meredith M Regan

4 joint publications

Michael B Atkins

4 joint publications

Toni K Choueiri

2 joint publications

Bradley McGregor